N B Amin1, N Aggarwal2, D Pall3, G Paragh3, W S Denney1, V Le1, M Riggs1, R A Calle1. 1. Worldwide Research and Development, Pfizer Inc, Cambridge, MA, USA. 2. Aggarwal & Associates Ltd, Brampton, Ontario, Canada. 3. Department of Medicine, University of Debrecen Medical and Health Science Centre, Nagyerdei krt, Hungary.
Abstract
AIM: To assess the efficacy and safety of a range of doses of a systemic, partial, glucokinase activator, PF-04937319, as add-on therapy to metformin, in patients with type 2 diabetes mellitus (T2DM). METHODS: Patients were randomized to once-daily PF-04937319 doses of 10, 50, 100 mg, or matching placebo (Study B1621002); or PF-04937319 doses of 3, 20, 50, 100 mg, or matching placebo (Study B1621007). Titrated glimepiride (Study B1621002) or sitagliptin (Study B1621007) were included in a double-dummy manner. The primary measure was change from baseline in glycated haemoglobin (HbA1c) at week 12. Key secondary measures included other glycaemic variables and safety and tolerability. RESULTS: In the 639 patients randomized, the minimally efficacious PF-04937319 dose was identified as 50 mg once daily. At the highest PF-04937319 dose tested (100 mg), on average, a clinically significant reduction in HbA1c [-4.94 or -5.11 mmol/mol (-0.45 or -0.47%), placebo-adjusted], which was similar to that achieved with sitagliptin [-4.69 mmol/mol (-0.43%)] but lower than that achieved with titrated glimepiride [-9.07 mmol/mol (-0.83%)], was observed. At this dose, the effect on fasting plasma glucose was not consistent between the two studies (Study B1621002 vs Study B1621007: placebo-adjusted mean change of -0.83 vs +0.50 mmol/l). PF-04937319 was well tolerated at doses up to 100 mg. Hypoglycaemia was reported in 2.5% of patients (on placebo), 5.1% of patients (on PF-04937319 100 mg), 1.8% of patients (on sitagliptin) and 34.4% of patients (on titrated glimepiride). CONCLUSIONS: In patients on metformin monotherapy, the addition of a 100-mg dose of PF-04937319 improved glycaemic control and was well tolerated.
RCT Entities:
AIM: To assess the efficacy and safety of a range of doses of a systemic, partial, glucokinase activator, PF-04937319, as add-on therapy to metformin, in patients with type 2 diabetes mellitus (T2DM). METHODS:Patients were randomized to once-daily PF-04937319 doses of 10, 50, 100 mg, or matching placebo (Study B1621002); or PF-04937319 doses of 3, 20, 50, 100 mg, or matching placebo (Study B1621007). Titrated glimepiride (Study B1621002) or sitagliptin (Study B1621007) were included in a double-dummy manner. The primary measure was change from baseline in glycated haemoglobin (HbA1c) at week 12. Key secondary measures included other glycaemic variables and safety and tolerability. RESULTS: In the 639 patients randomized, the minimally efficacious PF-04937319 dose was identified as 50 mg once daily. At the highest PF-04937319 dose tested (100 mg), on average, a clinically significant reduction in HbA1c [-4.94 or -5.11 mmol/mol (-0.45 or -0.47%), placebo-adjusted], which was similar to that achieved with sitagliptin [-4.69 mmol/mol (-0.43%)] but lower than that achieved with titrated glimepiride [-9.07 mmol/mol (-0.83%)], was observed. At this dose, the effect on fasting plasma glucose was not consistent between the two studies (Study B1621002 vs Study B1621007: placebo-adjusted mean change of -0.83 vs +0.50 mmol/l). PF-04937319 was well tolerated at doses up to 100 mg. Hypoglycaemia was reported in 2.5% of patients (on placebo), 5.1% of patients (on PF-04937319 100 mg), 1.8% of patients (on sitagliptin) and 34.4% of patients (on titrated glimepiride). CONCLUSIONS: In patients on metformin monotherapy, the addition of a 100-mg dose of PF-04937319 improved glycaemic control and was well tolerated.
Authors: Konstantinos A Toulis; Krishnarajah Nirantharakumar; Chrysa Pourzitaki; Anthony H Barnett; Abd A Tahrani Journal: Drugs Date: 2020-04 Impact factor: 9.546
Authors: Mikhail S Dzyurkevich; Denis A Babkov; Nikita V Shtyrlin; Olga Yu Mayka; Alfiya G Iksanova; Pavel M Vassiliev; Konstantin V Balakin; Alexander A Spasov; Vadim V Tarasov; George Barreto; Yurii G Shtyrlin; Gjumrakch Aliev Journal: Sci Rep Date: 2017-11-22 Impact factor: 4.379
Authors: Neeta B Amin; Amanda Darekar; Quentin M Anstee; Vincent Wai-Sun Wong; Frank Tacke; Manoli Vourvahis; Douglas S Lee; Michael Charlton; Naim Alkhouri; Atsushi Nakajima; Carla Yunis Journal: BMJ Open Date: 2022-03-30 Impact factor: 2.692
Authors: Kolade Olatubosun Faloye; Boris Davy Bekono; Emmanuel Gabriel Fakola; Marcus Durojaye Ayoola; Oyenike Idayat Bello; Oluwabukunmi Grace Olajubutu; Onikepe Deborah Owoseeni; Shafi Mahmud; Mohammed Alqarni; Ahmed Abdullah Al Awadh; Mohammed Merae Alshahrani; Ahmad J Obaidullah Journal: Molecules Date: 2021-11-28 Impact factor: 4.411